DBV TECHNOLOGIES News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

13.03.23	DBV Technologies Update (GlobeNewswire)
07.03.23	DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years Old (GlobeNewswire)
02.03.23	DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document (GlobeNewswire)
02.03.23	DBV Technologies Reports Full Year 2022 Financial Results and Business Update (GlobeNewswire)
27.02.23	DBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023 (GlobeNewswire)
21.02.23	DBV Technologies to Participate in Upcoming AAAAI 2023 Congress (GlobeNewswire)
10.02.23	DBV Technologies to Participate in Upcoming Investor Conference (GlobeNewswire)
22.11.22	DBV Technologies to Participate in Upcoming Investor Conference (GlobeNewswire)
09.11.22	DBV Technologies to Highlight New Clinical Data at ACAAI 2022 (GlobeNewswire)
03.11.22	DBV Technologies Reports Third Quarter Financial Results and Business Update (GlobeNewswire)
31.10.22	DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update (GlobeNewswire)
20.10.22	Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2022 (GlobeNewswire)
03.10.22	DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors (GlobeNewswire)
21.09.22	DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial (GlobeNewswire)
07.09.22	DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years (GlobeNewswire)
02.09.22	DBV Technologies to Present at Upcoming Investor Conferences (GlobeNewswire)
01.08.22	DBV Technologies Reports Second Quarter 2022 Financial Results (GlobeNewswire)
27.07.22	Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF (GlobeNewswire)
20.07.22	Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2022 (GlobeNewswire)
29.06.22	DBV Technologies to Participate in Upcoming EAACI 2022 Congress (GlobeNewswire)
16.06.22	DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York (GlobeNewswire)
09.06.22	DBV Technologies Announces Private Placement Financing of $194 Million (GlobeNewswire)
07.06.22	DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers (GlobeNewswire)
17.05.22	Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2022 (GlobeNewswire)
12.05.22	DBV Technologies Announces Results of Its 2022 Ordinary and Extraordinary General Meeting (GlobeNewswire)
05.05.22	DBV Technologies Completes ADSs Sale of an amount of $15.3 million on Nasdaq through its At-The-Market program (ATM) (GlobeNewswire)
02.05.22	DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq (GlobeNewswire)
02.05.22	DBV Technologies Reports Recent Business Developments and First Quarter 2022 Financial Results (GlobeNewswire)
25.04.22	DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments (GlobeNewswire)
21.04.22	Ordinary and Extraordinary General Meeting of May 12, 2022 (GlobeNewswire)
14.04.22	Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2022 (GlobeNewswire)
14.03.22	DBV Technologies to Present at the Oppenheimer’s 32nd Annual Healthcare Conference (GlobeNewswire)
11.03.22	Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 28, 2022 (GlobeNewswire)
09.03.22	DBV Technologies Announces Filing of 2021 Annual Report on Form 10-K and 2021 Universal Registration Document (GlobeNewswire)
03.03.22	DBV Technologies Reports Full Year 2021 Financial Results and Recent Business Updates (GlobeNewswire)
24.02.22	DBV Technologies to Report Full Year 2021 Financial Results and Business Updates on March 3, 2022 (GlobeNewswire)
22.02.22	DBV Technologies to Participate in Upcoming AAAAI 2022 Congress (GlobeNewswire)
14.02.22	DBV Technologies to Present at the 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire)
09.02.22	Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2022 (GlobeNewswire)
21.01.22	Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF (GlobeNewswire)
12.01.22	Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2021 (GlobeNewswire)
07.01.22	DBV Technologies to Present at the H.C. Wainwright BioConnect 2022 Conference (GlobeNewswire)
20.12.21	DBV Technologies Provides Update on Investigational Viaskin™ Peanut (GlobeNewswire)
10.12.21	Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2021 (GlobeNewswire)
24.11.21	DBV Technologies to Participate in an Upcoming Investor Conference (GlobeNewswire)
04.11.21	Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2021 (GlobeNewswire)
01.11.21	DBV Technologies to Highlight New Long-term Data from REALISE Trial at ACAAI 2021 (GlobeNewswire)
26.10.21	DBV Technologies Reports Third Quarter 2021 Financial Results and Recent Regulatory Developments (GlobeNewswire)
12.10.21	Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2021 (GlobeNewswire)
08.09.21	Monthly information regarding the total number of voting rights and total number of shares of the Company as of August 31, 2021 (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu DBV TECHNOLOGIES

Aktien Top/Flop

Meistgelesene Nachrichten